Pharmaron, Celgene, Amgen and Merck & Co-backed Imago BioSciences floated in an IPO today, alongside a private placement transaction featuring Pfizer.
Imago BioSciences, a US-based cancer treatment developer which counts contract research organisation Pharmaron and pharmaceutical firms Celgene, Amgen and Merck & Co as investors, is floating today in a $134m initial public offering.
The company increased the number of shares in the offering from 7 million to 8.4 million and is issuing them on the Nasdaq Global Select Market priced at the top end of the IPO’s $14 to $16 range, impliying a market capitalisation of approximately $534m. Pharmaceutical firm…
